Arrestin Pathways as Drug Targets - Progress in Molecular Biology and Translational Science - page 477

20. Appleton KM, Lee MH, Alele C, et al. Biasing the parathyroid hormone receptor:
relating in vitro ligand efficacy to in vivo biological activity. Methods Enzymol .
2013;522:229- 262.
21. Kohout TA, Nicholas SL, Perry SJ, Reinhart G, Junger S, Struthers RS. Differential
desensitization, receptor phosphorylation, beta-arrestin recruitment, and ERK1/2 acti-
vation by the two endogenous ligands for the CC chemokine receptor 7. J Biol Chem .
2004;279:23214 - 23222.
22. Drake MT, Violin JD, Whalen EJ, Wisler JW, Shenoy SK, Lefkowitz RJ. beta-
Arrestin-biased agonism at the beta2-adrenergic receptor. J Biol Chem . 2008;283:
5669- 5676.
23. Rajagopal S, Ahn S, Rominger DH, et al. Quantifying ligand bias at seven-

transmembrane receptors. Mol Pharmacol . 2011;80:367- 377.
24. Gesty-Palmer D, Chen M, Reiter E, et al. Distinct conformations of the parathyroid
hormone receptor mediate G protein and beta-arrestin dependent activation of ERK1/
2. J Biol Chem . 2006;281:10856- 10864.
25. Kenakin TP. 7TM receptor allostery: putting numbers to shapeshifting proteins. Trends
Pharmacol Sci . 2009;30:460- 469.
26. Bringhurst FR, Juppner H, Guo J, et al. Cloned, stably expressed parathyroid hormone
(PTH)/PTH-related peptide receptors activate multiple messenger signals and biolog-
ical responses in LLC-PK1 kidney cells. Endocrinology . 1993;132:2090- 2098.
27. Jouishomme H, Whitfield JF, Gagnon L, et al. Further definition of the protein kinase
C activation domain of the parathyroid hormone. J Bone Miner Res . 1994;9:943- 949.
28. Friedman PA, Gesek FA, Morley P, Whitfield JF, Willick GE. Cell specific signaling
and structure-activity relations of parathyroid hormone analogs in mouse kidney cells.
Endocrinology . 1999;140:301- 309.
29. SneddonWB, Magyar CE, Willick GE, et al. Ligand-selective dissociation of activation
and internalization of the parathyroid hormone receptor. Conditional efficacy of PTH
peptide fragments. Endocrinology . 2004;145:2815- 2823.
30. Gardella TJ, Luck MD, Jensen GS, Schipani E, Potts Jr JT, Juppner H. Inverse agonism
of amino-terminally truncated parathyroid hormone (PTH) and PTH-related peptide
(PTHrP) analogs revealed with constitutively active mutant PTH/PTHrP receptors.
Endocrinology . 1996;137:3936- 3941.
31. Gesty-Palmer D, Flannery P, Yuan L, Spurney R, Lefkowitz RJ, Luttrell LM. A beta-
arrestin biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone
formation independent of G protein activation. Sci Transl Med . 2009;1:1ra1.
32. Yao X, Parnot C, Deupi X, et al. Coupling ligand structure to specific conformational
switches in the beta2-adrenoceptor. Nat Chem Biol . 2006;2:417- 422.
33. Yao XJ, V´lez Ruiz G, Whorton MR, et al. The effect of ligand efficacy on the for-
mation and stability of a GPCR-G protein complex. Proc Natl Acad Sci USA .
2009;106:9501- 9506.
34. Liu JJ, Horst R, Katritch V, Stevens RC, W¨ thrich K. Biased signaling pathways in
b 2 -adrenergic receptor characterized by 19 F-NMR. Science . 2012;335:1106 - 1110.
35. Coulon V, Audet M, Homburger V, et al. Subcellular imaging of dynamic protein
interactions by bioluminescence resonance energy transfer. Biophys J . 2008;94:

1001- 1009.
36. Lohse MJ, Nuber S, Hoffmann C. Fluorescence/bioluminescence resonance energy
transfer techniques to study G-protein-coupled receptor activation and signaling.
Pharmacol Rev . 2012;64:299- 336.
37. Sauli`re A, Bellot M, Paris H, et al. Deciphering biased-agonism complexity reveals a
new active AT1 receptor entity. Nat Chem Biol . 2012;8:622- 630.
38. Wei H, Ahn S, Shenoy SK, et al. Independent G protein and beta-arrestin2 mediated
activation of ERK by angiotensin. Proc Natl Acad Sci USA . 2003;100:10782- 10787.